Health

Results: 277-288 of 5143

PR Newswire associated0

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

PR Newswire associated0

TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025

RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege.

RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product

Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

BioArctic receives Orphan Drug Designation for exidavnemab the US

PR Newswire associated0

Clario announces acquisition of imaging provider NeuroRx

Crack teams get patients off waiting lists at twice the speed

Curia Announces Expansions to Global Network of Sterile Fill-Finish Sites

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

Astronauts during space missions, deep-sea researchers, high-altitude climbers, and workers exposed to radiation hazards, are highly prone to hastened process of aging and inflammaging, reflected by increase in NLR, Interleukin-6, gut dysbiosis and immune dysfunction. Going by earlier pre-clinical & clinical studies where oral consumption of Nichi BRITE and Neu REFIX beta-glucans have shown to safely and beneficially modify those biomarkers including reduction of D-Dimer and Ferritin, besides Neu REFIX standalone reducing skeletal muscle fibrosis are considered holding potentials for benefitting those undertaking expeditions in hostile conditions. Upon validation, they could be included in the guidelines as an ingredient especially for space foods. These exo-polysaccharide beta glucans produced by unique strains of Aureobasidium Pullulans are food supplements and not a drug or remedy for any illness. Research outcomes are not to be construed as medical advice.

Astronauts’ Health During Space Missions: Nichi BRITE and Neu REFIX Beta Glucans Could Benefit by Neutrophil-to-Lymphocyte Ratio, IL-6 Control, the Immune Biomarkers of Aging and Longevity